Virax Biolabs Group (VRAX) Competitors $0.90 +0.01 (+1.11%) Closing price 07/11/2025 03:59 PM EasternExtended Trading$0.90 0.00 (0.00%) As of 07/11/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. SNPX, PHXM, TLPH, CLDI, ADXN, GOVX, GLYC, APRE, XFOR, and CYCNShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Synaptogenix (SNPX), PHAXIAM Therapeutics (PHXM), Talphera (TLPH), Calidi Biotherapeutics (CLDI), Addex Therapeutics (ADXN), GeoVax Labs (GOVX), GlycoMimetics (GLYC), Aprea Therapeutics (APRE), X4 Pharmaceuticals (XFOR), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Synaptogenix PHAXIAM Therapeutics Talphera Calidi Biotherapeutics Addex Therapeutics GeoVax Labs GlycoMimetics Aprea Therapeutics X4 Pharmaceuticals Cyclerion Therapeutics Virax Biolabs Group (NASDAQ:VRAX) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor VRAX or SNPX? In the previous week, Virax Biolabs Group and Virax Biolabs Group both had 1 articles in the media. Virax Biolabs Group's average media sentiment score of 1.89 beat Synaptogenix's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Overall Sentiment Virax Biolabs Group Very Positive Synaptogenix Very Positive Do analysts recommend VRAX or SNPX? Virax Biolabs Group presently has a consensus price target of $3.00, suggesting a potential upside of 233.33%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, research analysts plainly believe Virax Biolabs Group is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VRAX or SNPX more profitable? Virax Biolabs Group's return on equity of 0.00% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Virax Biolabs GroupN/A N/A N/A Synaptogenix N/A -115.28%-58.31% Which has more volatility & risk, VRAX or SNPX? Virax Biolabs Group has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Which has stronger valuation and earnings, VRAX or SNPX? Virax Biolabs Group has higher revenue and earnings than Synaptogenix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirax Biolabs Group$10K390.60-$6.06MN/AN/ASynaptogenixN/AN/A-$12.77M-$10.08-0.71 Do institutionals and insiders hold more shares of VRAX or SNPX? 8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryVirax Biolabs Group beats Synaptogenix on 10 of the 11 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.86M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E RatioN/A20.5827.9620.25Price / Sales390.60292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.717.638.045.49Net Income-$6.06M-$55.05M$3.18B$250.27M7 Day Performance4.05%8.54%3.67%4.80%1 Month Performance-6.25%5.51%4.09%7.68%1 Year Performance-20.35%2.03%29.58%16.36% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.1141 of 5 stars$0.90+1.1%$3.00+233.3%-21.1%$3.86M$10K0.005Positive NewsGap DownSNPXSynaptogenix0.3319 of 5 stars$7.63-10.2%$14.00+83.5%+63.3%$10.61MN/A-0.764PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049TLPHTalphera1.9992 of 5 stars$0.50+8.6%$5.00+894.8%-42.3%$10.31M$27K-1.1219Positive NewsCLDICalidi Biotherapeutics0.548 of 5 stars$0.32+33.6%N/A-50.1%$10.21MN/A0.0038News CoverageGap DownHigh Trading VolumeADXNAddex Therapeutics2.518 of 5 stars$9.52+1.5%$30.00+215.1%+5.8%$10.09M$460K-28.0030Gap DownGOVXGeoVax Labs2.2952 of 5 stars$0.63+25.4%$11.10+1,661.9%-76.7%$10.04M$3.95M-0.1710Analyst RevisionHigh Trading VolumeGLYCGlycoMimetics1.1325 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450High Trading VolumeAPREAprea Therapeutics2.9247 of 5 stars$1.80+4.0%$15.50+761.1%-56.9%$9.95M$1.50M-0.767XFORX4 Pharmaceuticals4.9392 of 5 stars$1.69flat$72.33+4,192.8%-93.1%$9.76M$2.56M0.7980News CoverageHigh Trading VolumeCYCNCyclerion Therapeutics2.0083 of 5 stars$3.01-2.6%N/A+7.7%$9.66M$2M-2.5930Gap Down Related Companies and Tools Related Companies Synaptogenix Competitors PHAXIAM Therapeutics Competitors Talphera Competitors Calidi Biotherapeutics Competitors Addex Therapeutics Competitors GeoVax Labs Competitors GlycoMimetics Competitors Aprea Therapeutics Competitors X4 Pharmaceuticals Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRAX Stock Alerts